NIH Intramural Research Program

AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

Retrieved on: 
Thursday, September 1, 2022
PSP, PET, NLRP3, CEO, Janssen Pharmaceuticals, Spinocerebellar ataxia, Program, NOD, NIH Intramural Research Program, MJFF, Alpha-synuclein, AC, NASDAQ, Brain, Doctor of Philosophy, Time, Disease, Precision medicine, USD, Hoffmann-La Roche, Genentech, Diagnosis, The Michael J. Fox Foundation, DLB, Senior, MSA, GMP, GLOBE, PD, Company, Neurodegeneration, SCA, AD, Eli Lilly and Company, Patient, Multiple system atrophy, Medical imaging, Pharmaceutical industry

Fox Foundation for Parkinsons Research (MJFF) awarded the Company a new grant to continue development of its Morphomer-based alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589.

Key Points: 
  • Fox Foundation for Parkinsons Research (MJFF) awarded the Company a new grant to continue development of its Morphomer-based alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589.
  • AC Immunehas received continuous grant support from MJFF since 2015 to develop a-syn PET tracers.
  • If successful, AC Immunes a-syn PET tracer program could deliver the worlds first imaging agent capable of accurately detecting and monitoring progression of Parkinsons disease (PD).
  • ACI-12589 also displayed pharmacokinetic and safety profiles suitable for further development as a human brain PET imaging agent.

CooperVision to Share New Analysis of MiSight® 1 Day Treatment Effects During International Myopia Conference Event

Retrieved on: 
Thursday, September 1, 2022
Workforce, NYSE, Research, NIH Intramural Research Program, Awareness, Doctor of Philosophy, Disease, The Cooper Companies, Parent, ECP, Presbyopia, Learning, Science, Fertility, Dioptre, Myopia, Conference, Cooper, CEST, CooperVision, Clinical trial, Lens (anatomy), Woman, Bachelor of Science, Benelux, Astigmatism, Health, Genomics, Pharmaceutical industry, Telescopic sight, Honours degree, IMC

ROTTERDAM, Netherlands, Sept. 1, 2022 /PRNewswire/ -- CooperVision's global leadership in myopia control and management will be spotlighted next week at the 18th annual International Myopia Conference, taking place in Rotterdam, the Netherlands. The meeting is expected to attract a record number of attendees, reflecting escalating interest in understanding and addressing the disease and its bearing on children's short- and long-term vision and ocular health.

Key Points: 
  • The international seven-year MiSight1 day clinical trial has become the gold standard for evaluating myopia control effectiveness because of its robust design, multi-country enrollment, and extent of professionally published and peer-reviewed data.
  • The findings will be presented by Paul Chamberlain, BSc (Hons), CooperVision Senior Director of Research Programs, and Arthur Bradley, PhD, CooperVision Research Fellow, on Monday, September 5, at 12:30 pm CEST.
  • "No one is doing more than CooperVision to advance the science and practice of myopia control and management.
  • Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries.

ORAU Launches New App With a Variety of Resources Available, Including Hundreds of STEM Internships, Fellowships and Research Opportunities

Retrieved on: 
Thursday, August 4, 2022
Research, Apps, Applications, Mobile, Wireless, Technology, Other Education, Continuing, Training, University, Science, Education, United States Army Research Laboratory, STEM, ORAU, Science, Technology, Oak Ridge Institute for Science and Education, Research, Army, U.S. Department of Energy, Office of Inspector General, NASA, Engineering, U.S. Department of Defense Strategy for Operating in Cyberspace, Education, NIH Intramural Research Program, Student, Health, Online shopping

ORAU unveiled its all-new ORAU Pathfinder app , providing a wide range of resources on the go.

Key Points: 
  • ORAU unveiled its all-new ORAU Pathfinder app , providing a wide range of resources on the go.
  • The ORAU Pathfinder app also provides a platform to remain engaged, connected and informed during the ORAU experiencefrom application, to offer, through the appointment and even as an ORAU alum.
  • The ORAU Pathfinder mobile app helps those interested stay engaged, connected and informed during their experience at ORAU and beyond, and the app can be used to search and apply for opportunities, learn about exclusive ORAU events, manage applications, accept offers, access a variety of STEM career resources and more!
  • Visit ORAU Pathfinder app for more information and to download the app today!

ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology

Retrieved on: 
Wednesday, July 27, 2022
Goal, Inflammation, University, View, Phenotype, Multiple sclerosis, Kidney, Awareness, Center, Neurosurgery, Paralysis, ASC, Physiology, Traumatic brain injury, Twitter, Foundation, The Michael J. Fox Foundation, Parkinson's disease, Research, Government, FSGS, PFF, Associate, CNS, NIH Intramural Research Program, Therapy, Focal segmental glomerulosclerosis, Multimedia, DRS, Volunteering, Clinical trial, Fox Trial Finder, Ageing, Inflammasome, Cognitive neuroscience, Kidney disease, Miami, Patient, LinkedIn, Department, Stroke, Faculty, Microbiology, Alport syndrome, Invention, MJFF, Miami Project to Cure Paralysis, Pharmaceutical industry, Medicine, Immunology, Biophysics, Facebook

WESTON, Fla., July 27, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is honored to receive a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model. The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari. Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine. Dr. de Rivero Vaccari is an Associate Professor in the Department of Neurological Surgery and The Miami Project to Cure Paralysis, and a Distinguished Faculty Member of the Center for Cognitive Neuroscience and Aging at the University of Miami Miller School of Medicine.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF) to determine if IC 100 inhibition of inflammasomes and ASC specks blocks microglial-mediated inflammation in a PD model.
  • The research will be conducted at the University of Miami Miller School of Medicine in the labs of IC 100 inventors, Drs.
  • Dr. Keane is Professor, Departments of Physiology and Biophysics, Neurological Surgery and Microbiology, Immunology, and The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.

DLH Wins Renewal of National Institute of Health Contract for Statistical Support

Retrieved on: 
Thursday, June 2, 2022
Biology, Research, Science, Carcinogenesis, Artificial intelligence, Public health, CEO, Partnership, DLH, Solution, National Institute of Environmental Health Sciences, Neurotoxicity, NIH Intramural Research Program, GLOBE, Division, Health, National Toxicology Program, DIR, NASDAQ, Toxicology, Disease, Climate change, National Institute, NIEHS, Data visualization, Medicine, Management

The contract includes a base period of one year with four one-year options, for a total value of approximately $13 million.

Key Points: 
  • The contract includes a base period of one year with four one-year options, for a total value of approximately $13 million.
  • Under this award, DLH will provide statistical analysis, research support, software programing, and data visualization for NIEHS Division of National Toxicology Program (DNTP) and Division of Intramural Research (DIR).
  • The DLH team will continue to employ innovative statistical approaches that keep step with emerging technologies and new scientific approaches to support the crucial public health work of NIEHS.
  • DLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, systems development, and innovative care processes.

Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

Retrieved on: 
Wednesday, May 25, 2022
Department, Severe acute respiratory syndrome coronavirus 2, CEO, Risk, Lists of diseases, Private Securities Litigation Reform Act, Observational study, Institute for Music and Neurologic Function, NIH Intramural Research Program, National Institute of Neurological Disorders and Stroke, Leadership, National Institute, Patient, BVA, COVID-19, Mortality, NIH, FDA, Blood volume, Critical care, U.S. Department of Defense Strategy for Operating in Cyberspace, NINDS, Forward-looking statement, Department of Defense Serum Repository, Heart failure, Orthostatic intolerance, National, Exercise intolerance, SEC, GLOBE, Hypertension, Pharmaceutical industry, Stroke

Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.

Key Points: 
  • Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.
  • Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.

SITC's Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology

Retrieved on: 
Tuesday, May 10, 2022
Society, Society for Immunotherapy of Cancer, Child, YouTube, Twitter, NIH, Patient, Immunotherapy, Doctor of Philosophy, National Cancer Institute, NIH Intramural Research Program, National, Cancer, Hospital, MD, Facebook, LinkedIn, Science, Education, Conference, Research, SITC, NCI, Pharmaceutical industry, Management

MILWAUKEE, May 10, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award. Established in 2020 in honor of Dr. Rosenberg, this award recognizes his many contributions to the field by supporting investigators who are emerging leaders in immuno-oncology and are focused on a novel approach to moving the field of immunology and cancer immunotherapy forward. The recipient will receive $150,000 in research funding and be recognized during an Award Ceremony at SITC's 37th Annual Meeting & Pre-Conference Programs (SITC 2022) this November.

Key Points: 
  • The Society for Immunotherapy of Cancer (SITC) is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award.
  • MILWAUKEE, May 10, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the call for nominations for the 2022 Steven A. Rosenberg Scholars Award .
  • The recipient will receive $150,000 in research funding and be recognized during an Award Ceremony at SITC's 37th Annual Meeting & Pre-Conference Programs (SITC 2022) this November.
  • As Chief of Surgery, he oversees an extensive clinical program to translate scientific advances into effective immunotherapies for patients with cancer.

NORD Announces over $100,000 in Grant Funding Available for Rare Disease Research

Retrieved on: 
Friday, April 29, 2022
LYS, US Food Sovereignty Alliance, National Organization for Rare Disorders, NORD, Patient, FDA, Orphan Drug Act of 1983, RFP, National Institutes of Health, Microdeletion syndrome, APS-1, MMIHS, Degenerative disease, Multimedia, Program, APS, NIH Intramural Research Program, National, NIH, Food and Drug Administration, Disease, Pharmaceutical industry, Medical device

WASHINGTON, April 29, 2022 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) announced three new requests for proposal (RFP) for grant funding related to the following rare diseases: Autoimmune Polyglandular Syndrome Type 1 (APS-1), Levy-Yeboa Syndrome (LYS), and Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS). The NORD Jayne Holtzer Rare Disease Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research. NORD's program provides grants for the study of diseases for which there are few other sources of funding.

Key Points: 
  • The NORD Jayne Holtzer Rare Disease Research Grants Program provides seed-money grants to qualified investigators for scientific and clinical research.
  • With funding from the APS Type 1 Foundation , NORD is accepting applications for one grant of $50,000 for scientific and/or clinical research studies related to APS-1.Deadline for letters of intent is Tuesday, June 21.
  • With funding from the MMIHS Foundation , NORD is accepting applications for one grant of $30,000 for scientific and/or clinical research studies related to MMIHS.
  • To learn more or submit to the 2022 NORD Research Grants Cycle, visit the NORD website .

New Chief Scientific Officer Takes Helm at the Christopher & Dana Reeve Foundation

Retrieved on: 
Monday, April 25, 2022
Christopher and Dana Reeve Foundation, Administration for Community Living, CEO, BBB, Clinical trial, Paralysis, Spinal cord, Administration, Parkinson's disease, International Spinal Cord Society, NIH Intramural Research Program, University, McMaster University, Research, Lists of diseases, The Michael J. Fox Foundation, Neuroscientist, SCI, Community Living British Columbia, Central nervous system, Better Business Bureau, Merck, University of Louisville School of Medicine, Walking, Technology, Movement, Schering-Plough, Big Idea, Foundation, LRRK2, Partnership, NPRC, Industry, Quality of life, Multimedia, Health, Toronto, Therapy, Time, SHORT, Medical device, Pharmaceutical industry

SHORT HILLS, N.J., April 25, 2022 /PRNewswire/ -- The Christopher & Dana Reeve Foundation today announced the appointment of Marco Baptista, Ph.D., Chief Scientific Officer. Dr. Baptista will help lead the Foundation's mission to advance cures for spinal cord injury (SCI) and paralysis and will provide scientific and innovative oversight of the nonprofit's collaborative approach to accelerating the field toward meaningful therapeutics.

Key Points: 
  • SHORT HILLS, N.J., April 25, 2022 /PRNewswire/ -- The Christopher & Dana Reeve Foundation today announced the appointment of Marco Baptista, Ph.D. , Chief Scientific Officer.
  • Dr. Baptista joins the Reeve Foundation from the Michael J.
  • The Christopher & Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for individuals and families impacted by paralysis.
  • The Reeve Foundation is committed to elevating our community's voices and needs to achieve greater representation and independence.

Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation

Retrieved on: 
Monday, April 11, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Rett syndrome, Mitochondrion, Therapy, Lists of diseases, Population, Bristol Myers Squibb, MJFF, Retirement, Peripheral nervous system, HIV disease progression rates, Coronavirus Scientific Advisory Board (Turkey), CNS, Research, Doctor of Philosophy, Medtronic, Pathology, The Michael J. Fox Foundation, NIH Intramural Research Program, Incidence, Conference, Parkinson's disease, CEO, Golden Ticket (The Office), Technology, Biology, 96th Street station (IND Eighth Avenue Line), Time, LabCentral, Gene, Drug discovery, Sanofi, Patient, Disease, MIT, Pharmaceutical industry, Engine, Biogen, Lundbeck

Lucy Therapeutics (LucyTx), a biotech with a unifying mitochondrial platform, today announced it secured funding from The Michael J.

Key Points: 
  • Lucy Therapeutics (LucyTx), a biotech with a unifying mitochondrial platform, today announced it secured funding from The Michael J.
  • Fox Foundation for Parkinsons Research (MJFF), the largest nonprofit funder of Parkinson's disease research.
  • The grant, valued at $4.9 million, will be used for continued investment into LucyTxs mitochondrial platform, including the development of potential novel medicines.
  • This additional capital will accelerate LucyTxs mission to advance therapeutics for CNS diseases through focus on disease-bottleneck targets rather than genetically implicated targets.